Use of Intralesional and Perilesional Human Recombinant Epidermal Growth Factor (hrEGF) in the Local Treatment of Venous Ulcer – Review Article – Expert Recommendation

Abstract

Venous Ulcers (VU) represent 60-80% of all leg ulcers and are the final stage of the disease secondary to venous hypertension or valve insufficiency. Conventional treatment that focuses on its etiological factors continues to be the gold standard; however, 30% of ulcers do not heal with this treatment; thus, it has been seen that the use of growth factor can be used as an adjuvant for this pathology. A literature review was carried out to evaluate the evidence from systematic reviews, meta-analyses, case studies, and quantitative studies that respond to the objective of this analysis review in the different databases with specific inclusion criteria with publications between 2002 and 2022, initially finding the topical application of the factor and later, more recently, the intralesional and perilesional application, the latter being an alternative treatment for this type of pathology and generating some recommendations for using the Factor.

Effectiveness of the Use of the Human Recombinant Epidermal Growth Factor in the Subsidized Regime vs The Contributive Regime in Patients with Venous Ulcers in Bogotá

“…37 However, a review and recommendation of experts specifies that perilesional and intralesional application is the most appropriate recommendation for the treatment of venous ulcers. 18 …”

“…In Colombia, there is the Colombian Guide for the Diagnosis and Management of Chronic Venous Disorders (GCDMDCV), which has been developed and updated by Angiology and Vascular Surgery – Asovascular which, since 2009, determines the type of therapeutic management that this type of pathology should have, 17 in addition, a series of recommendations were also generated by a group of experts for the use of rhEGF, with intralesional and perilesional application in venous ulcers, both in daily practice and in the generation of new studies with this medication, which are base documents for the treatment of this pathology in the Colombian health system. 18 …”